Tom Powles/X
Jun 28, 2025, 23:49
Tom Powles: BCG pretreated NMIBC is Moving Fast in The USA With Rapid FDA Approvals
Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“BCG pretreated NMIBC is moving fast in the USA with rapid FDA approvals from single arm trials.
The drugs look active but ‘rapid’ study design creates uncertainty.
Europe is going in a different direction, both can’t be right?”
More posts featuring Tom Powles
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 20:20
Jul 20, 2025, 20:10
Jul 20, 2025, 19:54
Jul 20, 2025, 19:20
Jul 20, 2025, 18:59
Jul 20, 2025, 18:27
Jul 20, 2025, 18:12
Jul 20, 2025, 17:37